BridgeMD
New treatment option for Hip Osteoarthritis
Official title The Role of Surgical Approach on Residual Limping After Total Hip Arthroplasty
ClinicalTrials.gov ID: NCT05216666
What this study is testing
- What it's testing
- Residual limping after total hip arthroplasty is empirically associated with the use of lateral approach but has been reported in litterature even with the use of posterior approach. The purpose of this clinical trial is to compare the risk of residual limping one year after total hip arthropasty between lateral and posterior approach.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 80
You may be able to join if
- Primary unilateral osteoarthritis of the hip scheduled for total hip arthroplasty.
- Ability to understand and write swedish.
You likely can't join if
- Impaired funktion of the contralateral hip or knees causing limping.
- Neuromuscular diseases
- Postoperative leg length discrepancy excceding 1 cm
- Postoperative discrepancy in femoral offset exceeding 25% of the femoral offset of the contralateral hip.
The study team makes the final eligibility decision.
Where it's taking place
- Mölndal, Sweden
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mölndal, Sweden. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.